STAT3 and neoplasm: Importantly, we had previously shown that therapeutic treatment of tumor‐bearing, 10‐ to 13‐week‐old gp130Y757F mice with either the antagonistic IL11‐Mutein peptide (Putoczki et al, 2013), JAK1/2 kinase inhibitors (Stuart et al, 2014), STAT3 antisense oligonucleotides (Ernst et al, 2008), or inducible short hairpin STAT3‐RNA (Alorro et al, 2017), reduces tumor burden associated with reduced cell proliferation and increased apoptosis.